OphthaliX (OTCBB: OPLI) has completed preclinical studies showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis. The pre-clinical study data demonstrated that CF101 is efficacious in preventing the clinical manifestations of Anterior Uveitis in a well-established animal model. The current study data together with the previous published results showing the efficacy of CF101 in preventing Posterior Uveitis, strongly support the utilization
Prof. Pnina Fishman, interim CEO and Chairman of OphthaliX noted that the company is conducting all the preparatory work for a phase 2 study in Uveitis in addition to the ongoing studies in Dry Eye Syndrome and Glaucoma.
Can-Fite recently licensed its activity in the ophthalmic field to OphthaliX Inc.
OphthaliX Inc. (OTCBB: DCMG) is an advanced clinical-stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. Denali`s product candidate, CF101, is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis.Can-Fite holds 82.3% in OphthaliX Inc.